Naturalendo Tech Co., Ltd. (KOSDAQ:168330)
South Korea · Delayed Price · Currency is KRW 2,060.00
-130.00 (-5.94%)
At close: Apr 2, 2026
Naturalendo Tech Revenue
In the year 2025, Naturalendo Tech had annual revenue of 22.23B KRW, down -0.16%. Naturalendo Tech had revenue of 5.18B in the quarter ending December 31, 2025, with 7.28% growth.
Revenue
22.23B
Revenue Growth
-0.16%
P/S Ratio
3.11
Revenue / Employee
274.40M
Employees
81
Market Cap
69.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.23B | -36.68M | -0.16% |
| Dec 31, 2024 | 22.26B | 3.47B | 18.48% |
| Dec 31, 2023 | 18.79B | 4.84B | 34.69% |
| Dec 31, 2022 | 13.95B | -744.85M | -5.07% |
| Dec 31, 2021 | 14.70B | 1.45B | 10.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 123.77B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Ark Solutions | 16.08B |
| PanGen Biotech | 13.42B |
| HLB Pep | 4.96B |
| EyeGene | 3.57B |
| SunBio,Inc. | 2.17B |
| Aptamer Sciences | 1.08B |